
![]() | ![]() |
Formats:
|
||||||||||||||||||
Synthetic and Biosynthetic Studies on FR900482 and Mitomycin C: An Efficient and Stereoselective Hydroxy-methylation of an Advanced Benzazocane Intermediate 1 Department of Chemistry, Colorado State University Fort Collins, Colorado 80523-1872 2 University of Colorado Cancer Center, Aurora, Colorado 80045 Email: rmw/at/lamar.colostate.edu Abstract ![]() We report a simple, efficient, and stereoselective Mukaiyama aldol approach to install the key hydroxymethyl moiety into the benzazocane framework of FR900482. Synthetic investigations revealed that the reaction is highly dependent upon the electronics of the aromatic ring. This approach enabled the economical introduction of a [13C]-label to study the biosynthesis of these structurally and biogenetically related natural products. Epimerization of the initially formed β-hydroxy ketone may enable access to mitomycin C or FR900482 biosynthetic congeners. FR900482 (2) and congeners FR66979 (3), FK973 (4), and FK317 (5) have enormous potential as anticancer agents (Figure 1
Throughout the course of our studies towards the synthesis of putative biosynthetic intermediates of both FR900482 and the mitomycins, it became necessary to investigate the hydroxymethylation of substrates such as 6 (Scheme 1
With benzazocane 6 in hand, we explored alternate hydroxymethylation conditions. We were especially intrigued by the lanthanide triflate-catalyzed Mukaiyama aldol reaction of enoxysilanes developed by Kobayashi.11 Accordingly, treatment of benzazocane 6 with trimethylsilyl triflate provided the silyl enol ether which was used without purification in the hydroxymethylation step. Exposing the enoxysilane to a catalytic amount of ytterbium(III) triflate and five equivalents of formaldehyde over 48 hours provided alcohol 7 in 70% yield as a 84:16 ratio of diastereomers. Scandium(III) triflate was a superior catalyst and furnished the alcohol 7 in 82% yield (75% over two steps) as a 91:9 ratio of diastereomers in only three hours (Scheme 1 Having developed an efficient method for the hydroxymethylation of benzazocane 6, we were interested in exploring the scope and generality of this protocol with more substrates. Specifically, we were interested to see the effect, if any, different protecting groups on the benzazocane nitrogen might have on the selectivity and general outcome of the aldol reaction. Consequently, N-alloc benzazocane 10a was prepared from compound 94 (Scheme 2
With these interesting results in hand for benzazocanes constituted with the FR900482 framework, we were intrigued whether this methodology could be useful in our studies towards the asymmetric total synthesis of the mitomycins and their corresponding biosynthetic precursors. As shown in Scheme 3
From the hydroxymethylation results for both FR900482- and mitomycin-based benzazocanes, we surmise that the electronics of the substrate play a crucial role in the success of this reaction. This observation is not without precedent for this family of molecules. Illustrated in Scheme 4
One powerful and unanticipated consequence of the Lewis acid-catalyzed Mukaiyama aldol approach is that it may be used for the construction of either the FR900482 or the MMC scaffold. Because the hydroxymethylation reaction is stereoselective and kinetically controlled, the initially formed 7S-stereoisomer of compound 11 matches the C-9 stereochemistry of MMC (1). On the other hand, equilibration of compound 11 to the thermodynamically favored 7R-isomer 16 under carefully controlled, base-catalyzed conditions should allow access to FR900482, potential late-stage biosynthetic intermediates and their congeners (Scheme 5
We attempted to develop a rationale to accommodate why the 7S-configuration predominates in successful hydroxymethylation reactions of FR900482-derived templates. Because reactions of medium-ring olefins are known to proceed from the periphery, the major, kinetic product of the hydroxymethylation reaction results from addition to the lowest energy conformation of the ring.15,16 The possible low-energy conformations of the intermediates in these reactions were determined and analyzed using computational methods (Figure 2
In summary, we report an efficient method for the hydroxymethylation of benzazocanes en route to putative synthetic and late-stage biosynthetic intermediates of FR900482 and MMC. Electronics play a major role in this reaction, as N-Nvoc and N-PMB benzazocanes of FR900482 fail to undergo hydroxymethylation. Efforts to prepare putative biosynthetic intermediates of FR900482 and the mitomycins, as well as the asymmetric total synthesis of the mitomycins, are currently under investigation in these laboratories. 1File001: Supporting Information Available Complete experimental procedures, characterization data, and spectral data for new compounds, details of theoretical experiments, and crystallographic data in CIF format. This material is available free of charge via the Internet at http://pubs.acs.org Click here to view.(13K, cif) 2File002 Click here to view.(3.3M, pdf) Acknowledgments Dedicated to the memory of Professor Albert I. Meyers. This work was supported by the National Institutes of Health (CA51875). We also acknowledge a Graduate Student Fellowship from Eli Lilly (to D.A.G.). Mass spectra were obtained on instruments supported by the NIH Shared Instrumentation Grant GM49631. References 1. (a) Boger DL, Wolkenberg SE. Chem Rev. 2002;102:2477. [PubMed] (b) Rajski SR, Williams RM. Chem Rev. 1998;98:2723. [PubMed] 2. (a) Nelson SM, Ferguson LR, Denny WA. Cell & Chromosome. 2004;3:2. [PubMed] (b) Beckerbauer L, Tepe J, Eastman RA, Mixter PF, Williams RM, Reeves R. Chem Biol. 2002;9:427. [PubMed] (c) Beckerbauer L, Tepe J, Cullison J, Reeves R, Williams RM. Chem Biol. 2000;7:805. [PubMed] 3. Bradner WT. Cancer Treat Rev. 2001;27:35. [PubMed] 4. Ducept P, Gubler DA, Williams RM. Heterocycles. 2006;67:597. and references cited therein. 5. (a) Judd TC, Williams RM. J Org Chem. 2004;69:2825. [PubMed] (b) Judd TC, Williams RM. Angew Chem Int Ed Engl. 2002;41:4683. [PubMed] 6. Prepared in two steps (TASF-mediated desilylation, Dess-Martin oxidation) from the corresponding silyl ether 12a reported in ref. 4. 7. Paleo MR, Aurrecoechea N, Jung KY, Rapoport H. J Org Chem. 2003;68:130. [PubMed] 8. The benzylic, exocyclic olefin in Danishefsky’s synthesis of FR900482 was the product of a Heck cyclization: Schkeryantz JM, Danishefsky SJ J Am Chem Soc. 1995;117:4722. 9. Suzuki M, Kambe M, Tokuyama H, Fukuyama T. J Org Chem. 2004;69:2831. [PubMed] 10. For example, 13CH2O solution, 20 wt. % in H2O, 99% 13C, CAS No. 3228-27-1, Aldrich Catalog No. 489417, costs US$266.00/gram. 11. (a) Kobayashi S, Hachiya I. J Org Chem. 1994;59:3590. [PubMed] (b) Ishikawa S, Hamada T, Manabe K, Kobayashi S. J Am Chem Soc. 2004;126:12236. [PubMed] 12. X-ray data for compound 8 is included as Supporting Information. 13. Williams RM, Rollins SB, Judd TC. Tetrahedron. 2000;56:521. 14. Prepared in two steps (TASF-mediated desilylation, Dess-Martin oxidation) from the corresponding silyl ether 13b reported in ref. 4. 15. Still WC, Galynker I. Tetrahedron. 1981;37:3981. 16. This statement is valid if we assume that the energy barrier of reaction between both conformations of the olefin and the electrophile are nearly identical, according to Curtin-Hammett/Winstein-Holness kinetics; see: Seeman JI J Chem Educ. 1986;63:42. 17. The lowest energy conformations of the eight-membered ring possessing a cis-olefin were determined by a Monte Carlo conformational search. These structures were refined using AM1, then HF/6-31G*. Lastly, the energies shown represent single-point HF/6-31G** calculations. Certain structural simplifications were made to simplify our qualitative computational experiments. These simplifications reduce computational time but do not, in our opinion, significantly alter the results. Further details and a rationale for the computational methods used are included in the Supporting Information. 18. Hammond GS. J Am Chem Soc. 1955;77:334. 19. Hoffmann RW. Chem Rev. 1989;89:1841. |
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||||||
Chem Rev. 2002 Jul; 102(7):2477-95.
[Chem Rev. 2002]Cell Chromosome. 2004 May 24; 3(1):2.
[Cell Chromosome. 2004]Cancer Treat Rev. 2001 Feb; 27(1):35-50.
[Cancer Treat Rev. 2001]J Org Chem. 2004 Apr 16; 69(8):2825-30.
[J Org Chem. 2004]J Org Chem. 2003 Jan 10; 68(1):130-8.
[J Org Chem. 2003]J Org Chem. 2004 Apr 16; 69(8):2831-43.
[J Org Chem. 2004]J Am Chem Soc. 2004 Oct 6; 126(39):12236-7.
[J Am Chem Soc. 2004]J Org Chem. 2004 Apr 16; 69(8):2825-30.
[J Org Chem. 2004]J Org Chem. 2004 Apr 16; 69(8):2831-43.
[J Org Chem. 2004]J Org Chem. 2004 Apr 16; 69(8):2831-43.
[J Org Chem. 2004]J Org Chem. 2003 Jan 10; 68(1):130-8.
[J Org Chem. 2003]J Org Chem. 2004 Apr 16; 69(8):2825-30.
[J Org Chem. 2004]J Org Chem. 2004 Apr 16; 69(8):2831-43.
[J Org Chem. 2004]